Article preview from "The Pink Sheet" DAILY June 30, 2009
Strong growth prospects for the global generic biologics space over the next decade are bringing together the world's third-largest generic drug maker Mylan and India's Biocon. The two signed a comprehensive deal June 29, which will divide development and certain other costs to bring bio-generics to the market. Read on...
Article preview from "The Pink Sheet" DAILY June 30, 2009
Through the deal, Mylan will hold exclusive commercialization rights in the U.S., EU, Canada, Japan, Australia, New Zealand and the European Free Trade Association countries. Biocon, India's second-largest biotech, will participate in profit-sharing in those markets, while the two companies will share commercialization rights in all other markets.
Mylan CEO Robert J. Coury said the tie-up will combine Biocon's scientific expertise, product development capabilities and "cost-efficient and scalable biologics manufacturing" with Mylan's global commercial footprint and regulatory expertise.
Purchase this article or sign-up for a free trial to "The Pink Sheet" DAILY today by clicking here!
